Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab plasma cell depletion trial for Graves' disease
ISRCTN81162400Phase 2Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of daratumumab in Graves' disease, sponsored by Newcastle Hospitals NHS Foundation Trust. Started Sep 2021; status: completed.
02
Drugs
daratumumab
03
Conditions
Graves' disease
Beyond the preview
Go deeper on ISRCTN81162400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN81162400.